Drug Profile
AE IG
Alternative Names: AE-IG; Genetic vaccine - NuGenerex Immuno-OncologyLatest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Antigen Express
- Developer NuGenerex Immuno-Oncology
- Class DNA vaccines; Small interfering RNA
- Mechanism of Action Helper-inducer T-lymphocyte stimulants; Invariant chain inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inborn genetic disorders
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Inborn genetic disorders in USA (Parenteral)
- 26 Apr 2016 Phase I development is ongoing in USA
- 03 Dec 2012 Phase-I clinical trials in Inborn genetic disorders in USA (Parenteral)